{"brief_title": "Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease", "brief_summary": "The purpose of this clinical research study is to assess the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease.", "condition": ["Parkinson's Disease", "Psychoses"], "intervention_type": ["Drug"], "intervention_name": ["aripiprazole"], "description": ["Tablets, Oral, 1-10mg, Once daily, 6 weeks."], "arm_group_label": ["A"], "other_name": ["Abilify"], "criteria": "Inclusion Criteria: - Primary diagnosis of idiopathic Parkinson's disease. - Psychosis related to Parkinson's disease. Exclusion Criteria: - Psychosis present prior to diagnosis of Parkinson's disease.", "gender": "All", "minimum_age": "50 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Psychosis, Parkinson's Disease", "mesh_term": ["Parkinson Disease", "Psychotic Disorders", "Mental Disorders", "Aripiprazole"], "id": "NCT00095810"}